TY - JOUR
T1 - Documento de consenso sobre la neumonía adquirida en la comunidad en los niños. SENP-SEPAR-SEIP
AU - Escribano Montaner, Amparo
AU - Moreno Galdó, Antonio
AU - García García, Maria Luz
AU - Rodrigo-Gonzalo de Liria, Carlos
AU - Figuerola Mulet, Joan
AU - Andrés-Martín, Anselmo
AU - Korta Murua, Javier
AU - Moreno-Pérez, David
N1 - Copyright © 2020 SEPAR. Publicado por Elsevier España, S.L.U. All rights reserved.
PY - 2020/11
Y1 - 2020/11
N2 - Community-acquired pneumonia (CAP) is a prevalent disease among children and is frequently associated with both diagnostic and therapeutic uncertainties. Consensus has been reached between SEPAR, SENP and SEIP, and their conclusions are as follows: 1. Etiology depends mainly on age and other factors and no single analytical marker offers absolute diagnostic reliability. 2. In the event of clinical suspicion of pneumonia in a healthy child, chest X-ray is not necessary. Chest ultrasound is increasingly implemented as a follow-up method, and even as a diagnostic method. 3. The empirical antibiotic treatment of choice In typical forms of the disease is oral amoxicillin at a dose of 80 mg/kg/day for 7 days, while in atypical presentations in children older than 5 years, macrolides should be selected. In severe typical forms, the combination of 3 rd generation cephalosporins and cloxacillin (or clindamycin or vancomycin) administered intravenously is recommended. 4. If pleural drainage is required, ultrasound-guided insertion of a small catheter is recommended. Intrapleural administration of fibrinolytics (urokinase) reduces hospital stay compared to simple pleural drainage. 5. In parapneumonic pleural effusion, antibiotic treatment combined with pleural drainage and fibrinolytics is associated with a similar hospital stay and complication rate as antibiotic treatment plus video-assisted thoracoscopy. 6. Systematic pneumococcal conjugate vaccination is recommended in children under 5 years of age, as it reduces the incidence of CAP and hospitalization for this disease.
AB - Community-acquired pneumonia (CAP) is a prevalent disease among children and is frequently associated with both diagnostic and therapeutic uncertainties. Consensus has been reached between SEPAR, SENP and SEIP, and their conclusions are as follows: 1. Etiology depends mainly on age and other factors and no single analytical marker offers absolute diagnostic reliability. 2. In the event of clinical suspicion of pneumonia in a healthy child, chest X-ray is not necessary. Chest ultrasound is increasingly implemented as a follow-up method, and even as a diagnostic method. 3. The empirical antibiotic treatment of choice In typical forms of the disease is oral amoxicillin at a dose of 80 mg/kg/day for 7 days, while in atypical presentations in children older than 5 years, macrolides should be selected. In severe typical forms, the combination of 3 rd generation cephalosporins and cloxacillin (or clindamycin or vancomycin) administered intravenously is recommended. 4. If pleural drainage is required, ultrasound-guided insertion of a small catheter is recommended. Intrapleural administration of fibrinolytics (urokinase) reduces hospital stay compared to simple pleural drainage. 5. In parapneumonic pleural effusion, antibiotic treatment combined with pleural drainage and fibrinolytics is associated with a similar hospital stay and complication rate as antibiotic treatment plus video-assisted thoracoscopy. 6. Systematic pneumococcal conjugate vaccination is recommended in children under 5 years of age, as it reduces the incidence of CAP and hospitalization for this disease.
KW - VATS
KW - Pleural drainage
KW - Complications
KW - Etiology
KW - Antibiotic therapy
KW - Community-acquired pneumonia
KW - Diagnosis
KW - Fibrinolytic
UR - https://dialnet.unirioja.es/servlet/articulo?codigo=7648975
UR - https://www.mendeley.com/catalogue/c631b0a5-4e1f-3ef4-a0ee-eb51627a3fa9/
UR - http://www.scopus.com/inward/record.url?scp=85086362418&partnerID=8YFLogxK
U2 - 10.1016/j.arbres.2020.03.025
DO - 10.1016/j.arbres.2020.03.025
M3 - Artículo
C2 - 32534869
AN - SCOPUS:85086362418
SN - 0300-2896
VL - 56
SP - 725
EP - 741
JO - Archivos de Bronconeumologia
JF - Archivos de Bronconeumologia
IS - 11
ER -